Reviewing Sage Therapeutics Inc. (SAGE)’s and Aridis Pharmaceuticals Inc. (NASDAQ:ARDS)’s results

We are comparing Sage Therapeutics Inc. (NASDAQ:SAGE) and Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sage Therapeutics Inc. 84 -0.42 50.86M -13.51 0.00
Aridis Pharmaceuticals Inc. 5 0.00 5.59M -3.57 0.00

Table 1 demonstrates Sage Therapeutics Inc. and Aridis Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 has Sage Therapeutics Inc. and Aridis Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Sage Therapeutics Inc. 60,468,434.19% -60% -54.7%
Aridis Pharmaceuticals Inc. 109,823,182.71% -182.3% -112.2%

Liquidity

The Current Ratio and Quick Ratio of Sage Therapeutics Inc. are 12.7 and 12.7 respectively. Its competitor Aridis Pharmaceuticals Inc.’s Current Ratio is 3.6 and its Quick Ratio is 3.6. Sage Therapeutics Inc. can pay off short and long-term obligations better than Aridis Pharmaceuticals Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Sage Therapeutics Inc. and Aridis Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sage Therapeutics Inc. 0 2 7 2.78
Aridis Pharmaceuticals Inc. 0 0 1 3.00

The consensus target price of Sage Therapeutics Inc. is $170, with potential upside of 126.94%. Competitively the consensus target price of Aridis Pharmaceuticals Inc. is $7, which is potential -5.79% downside. The information presented earlier suggests that Sage Therapeutics Inc. looks more robust than Aridis Pharmaceuticals Inc. as far as analyst belief.

Institutional & Insider Ownership

Institutional investors held 98.75% of Sage Therapeutics Inc. shares and 1.3% of Aridis Pharmaceuticals Inc. shares. About 0.3% of Sage Therapeutics Inc.’s share are held by insiders. On the other hand, insiders held about 45.04% of Aridis Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sage Therapeutics Inc. -58.35% -53.53% -57.23% -62.66% -39.12% -32.71%
Aridis Pharmaceuticals Inc. -8.27% -2.42% -55.67% -44.13% -58.3% -54.51%

For the past year Sage Therapeutics Inc.’s stock price has smaller decline than Aridis Pharmaceuticals Inc.

Summary

Sage Therapeutics Inc. beats Aridis Pharmaceuticals Inc. on 7 of the 12 factors.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.